Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Dravet Syndrome Companies

Dravet Syndrome companies specialize in the research and development of therapies and interventions for this rare and severe form of epilepsy. These organizations play a vital role in improving the quality of life for individuals affected by Dravet Syndrome.

Dravet Syndrome Market

Latest Dravet Syndrome Companies Updates

Stoke Therapeutics (NASDAQ: STOK): Presented positive data from their Phase 2 open-label extension study of STK-001, an antisense oligonucleotide therapy targeting the SCN1A gene mutation responsible for Dravet Syndrome.

Eisai Inc.: Initiated a Phase 3 clinical trial called Momentum I to study the efficacy of lorcaserin as an adjuctive (add-on) treatment in Dravet Syndrome to reduce seizure frequency.

Encoded Therapeutics: Collaborating with Cook Children's Medical Center on a non-interventional study to identify potential biomarkers for Dravet Syndrome using GABA levels in the blood.

Zogenix Inc.: Partnered with the DSF to provide educational grants to healthcare professionals on the use of Fintepla (fenfluramine) for Dravet Syndrome treatment.

List of Dravet Syndrome Key companies in the market:

Biocodex

Biscayne Neurotherapeutics

Cyberonics

Epygenix Therapeutics

GW Pharmaceuticals

INSYS THERAPEUTICS

OPKO Health Inc.

Ovid Therapeutics

PTC Therapeutics

Dravet Syndrome Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.